 CAMBRIDGE, Mass.--BUSINESS WIRE--Axcella Nasdaq: AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator EMM compositions, today announced clearance of the companys first investigational new drug IND filing and provided an update on its product candidates, research and development activities and expected milestones for 2021. The year 2020 was a time of tremendous accomplishment for Axcella 